Diabetes drug semaglutide tested in dialysis patients for safety

NCT ID NCT07017270

Recruiting now Disease control Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide, a diabetes drug, is safe and tolerable for people with type 2 diabetes who are on dialysis. About 100 participants will either receive weekly semaglutide injections or standard care for 26 weeks. The goal is to see if patients can stick with the treatment and to gather data for a larger future trial on heart health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a GLP-1 receptor agonist, given as a weekly injection)
What this could lead to: If successful, this could show that semaglutide is safe for dialysis patients, potentially leading to better diabetes management and a larger trial on heart outcomes.
What could go wrong: This is a small, early-phase trial focused on safety and feasibility, not effectiveness. Side effects like nausea or low blood sugar may occur, and results may not apply to all dialysis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetes mellitus end stage renal failure type 2 diabetes mellitus wild type ABeta2M amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIALYSIS END STAGE KIDNEY DISEASE (ESRD) KIDNEY DISEASE, CHRONIC

Contacts and locations

Locations

Unity Health Toronto
RECRUITING

Toronto, Ontario, M5B1W8, Canada
Unity Health Toronto
RECRUITING

Toronto, Ontario, M5B1W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.